Robin K. Lee

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.

Cooley advised Guild, a career opportunity platform, on its $175 million Series F financing round, bringing the company’s valuation to $4.4 billion. Lawyers Matthew Dubofsky, Mystery Murphy and Paul Holmer led the Cooley team advising Guild.

Cooley advised Guild Education, an education platform that upskills workers and prepares companies for the future, on its $150 million Series E financing round, which brings its valuation to $3.75 billion. Partner Matt Dubofsky led the Cooley team advising Guild.

Cooley advised UiPath, the world’s leading robotics process automation software company, on its $1.5 billion initial public offering of 27,474,393 shares of Class A common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Partners Nicole Brookshire, Eric Jensen and Matthew Dubofsky led the Cooley team advising UiPath.